Skip to main
PCVX

Vaxcyte (PCVX) Stock Forecast & Price Target

Vaxcyte (PCVX) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 0%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Vaxcyte Inc. is positioned for potential substantial growth due to its promising product pipeline, particularly the VAX-31 vaccine, which is set to launch in 2028 and is projected to contribute significantly to a peak revenue estimate increase to $6.8 billion by 2040. The company has demonstrated strong Phase 1/2 clinical trial results, including meeting non-inferiority criteria against established vaccines, which could lead to positive regulatory outcomes and expanded market opportunities. Additionally, anticipated universal recommendations for PCV vaccinations among adults over 50 years old may further enhance the commercial landscape, increasing investor interest and providing momentum for the stock in the coming years.

Bears say

Vaxcyte Inc's stock outlook appears negative due to several fundamental risks, including potential delays in research and development, regulatory challenges, and disappointing clinical trial results that could hinder the commercial uptake of their vaccine candidates. The company's upcoming VAX-24 Phase 2 trial readout is anticipated with caution, as past investor expectations were not met, indicating a lack of confidence in achieving significant milestones in the highly competitive pediatric vaccine market. Moreover, the increasing scrutiny from regulatory bodies and the possibility that national vaccine guidelines may not endorse Vaxcyte's products further limit the company's commercial prospects.

Vaxcyte (PCVX) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 0% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vaxcyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vaxcyte (PCVX) Forecast

Analysts have given Vaxcyte (PCVX) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Vaxcyte (PCVX) has a Strong Buy consensus rating as of Mar 31, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $98, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $98, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vaxcyte (PCVX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.